It was found that stem cell-like CD133/PROM1HIGH patient-derived GBM cells harbored significantly higher basal levels of glycolytic enzymes compared to non-stem-like CD133/PROM1LOW patient-derived cells (GLUT1/SLC2A1: p < 0.001, PFKP: p < 0.05, ALDOA: p < 0.05, GAPDH: p < 0.05, ENO1: p < 0.001; PKM2: p < 0.01; Fig. 2b). This evidence concerns the gene GAPDH and glioblastoma.